An anti-neurofilament heavy polypeptide antibody detects NfH, a marker of axonal damage. Compare formats, uses, and validation tips for ELISA, WB, and IHC.
An anti-neurofilament heavy polypeptide antibody is a laboratory reagent that binds specifically to neurofilament heavy chain (NfH), a structural protein released from axons when nerve fibers in the brain or spinal cord are damaged. Researchers and clinical labs use these antibodies in ELISA, Western blot, immunohistochemistry, and single-molecule immunoassays to measure or visualize NfH in blood, cerebrospinal fluid, or tissue. The antibody itself is a detection tool, not a diagnosis — the result means something only when a clinician interprets it alongside other findings.
This guide covers what the antibody targets, where it is used, and what to verify before you buy or validate one.
What Is Neurofilament Heavy Polypeptide (NfH)?
Neurofilaments are the scaffolding proteins that give axons their shape and caliber. Three subunits assemble into a filament: light (NfL), medium (NFM), and heavy (NfH). If you are asking what is a polypeptide, the short answer is a chain of amino acids joined by peptide bonds — and NfH is a long, heavily modified one.
The polypeptide structure of NfH matters for antibody work because its tail domain carries dozens of phosphorylation sites known as KSP repeats. Many commercial antibodies are raised against that phosphorylated tail, while others recognize total NfH regardless of phosphate status.
Common polypeptide examples in neurobiology include NfL, GFAP, tau, and S100B, all of which are often measured alongside NfH in panel studies. Their behavior in immunoassays differs, though. NfH is far less abundant in blood than NfL, so assay sensitivity and antibody affinity matter more than they do for light-chain assays.
How an Anti-Neurofilament Heavy Polypeptide Antibody Works
Antibodies are Y-shaped proteins that bind a specific epitope. An anti-neurofilament heavy polypeptide antibody is selected or engineered so that its binding site fits a short sequence within NfH — often a phosphorylated KSP motif — and not the light or medium subunits.
An anti neurofilament heavy polypeptide antibody sold for research typically arrives as purified IgG, carrier-free antiserum, or a recombinant clone, with a stated host species, concentration, and conjugate.
Phosphorylation state is the biggest variable
NfH is one of the most heavily phosphorylated proteins in the mammalian nervous system. Antibodies raised against phospho-KSP epitopes can lose signal in tissue that has been dephosphorylated, or in blood samples where NfH has been partially proteolyzed.
Check whether the datasheet describes the immunogen as a phospho-peptide or a recombinant fragment, and whether the vendor has validated that clone in your sample type.
Formats at a glance
| Antibody format | Typical host | Common uses | Practical notes |
|---|---|---|---|
| Polyclonal | Rabbit, sheep | IHC, Western blot | Broad epitope recognition; higher lot-to-lot variability |
| Monoclonal | Mouse, rabbit | ELISA, Simoa, Western blot | Consistent lot performance; depends on a single epitope |
| Phospho-specific | Mouse, rabbit | Western blot, IHC | Detects phosphorylated KSP repeats; signal drops in dephosphorylated samples |
| Recombinant | Rabbit, human | All platforms | Sequence-defined, low batch variability, higher cost |
Where Anti-NfH Antibodies Are Used
- ELISA and Simoa: quantify NfH in serum, plasma, or CSF across research cohorts.
- Western blot: confirm expression or phosphorylation changes in tissue lysates.
- Immunohistochemistry: visualize axonal pathology in brain or spinal cord sections.
- Immunoprecipitation: enrich NfH before mass spectrometry.
Disease areas where NfH is studied include multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, stroke, and chemotherapy-induced peripheral neuropathy.
Elevated NfH in blood or cerebrospinal fluid generally reflects axonal injury rather than one specific disease. That is why NfH is described as a non-specific biomarker of neuronal damage.
How to Choose and Validate an Antibody
- Define your readout: total NfH or phosphorylated NfH?
- Match the host species to your secondary reagent and screen for cross-reactivity with NfL and NFM.
- Confirm the vendor has data in your matrix — serum, CSF, and formalin-fixed tissue behave very differently.
- Run positive and negative controls, including a peptide-competition or knockout control when available.
- Test at least two lots before committing to a large study.
Antibody selection should be matched to sample type, target phosphorylation state, and detection platform. A clone that performs beautifully in Western blot may fail completely in a bead-based immunoassay.
Limitations and Safety Notes
Most anti-NfH assays are used in research or as laboratory-developed tests, not as FDA-cleared stand-alone diagnostics. Results are interpreted by qualified professionals alongside imaging, clinical history, and other laboratory findings.
Antibodies themselves are reagents, but preserved antisera can contain sodium azide or other hazardous preservatives. Follow the safety data sheet, and handle human CSF and blood samples under appropriate biosafety precautions.
Search results for this query sometimes mix laboratory reagents with consumer products. A polypeptide serum marketed for skincare, for instance, contains cosmetic signaling peptides rather than NfH antibodies, and it has no role in an immunoassay.
Key Takeaways
- An anti-neurofilament heavy polypeptide antibody detects NfH, the heavy subunit of neurofilaments.
- NfH is a marker of axonal damage, not a disease-specific marker.
- Phosphorylation state and sample matrix drive antibody performance more than brand name does.
- Always validate in your own assay, and consult a healthcare professional before interpreting any neurofilament result in a patient.
Frequently Asked Questions
What does an anti-neurofilament heavy polypeptide antibody detect?
It detects neurofilament heavy chain (NfH), the largest of the three neurofilament subunits that form the axonal cytoskeleton. Because NfH is released into blood and cerebrospinal fluid when axons are injured, the antibody is used to measure or visualize that damage in research and clinical laboratory settings.
Is neurofilament heavy chain the same as NfL?
No. NfL is the light subunit, NFM is the medium subunit, and NfH is the heavy subunit; each is encoded by a different gene and differs in molecular weight. Antibodies raised against NfH do not reliably detect NfL, which is why many laboratories measure both markers separately.
Can a neurofilament heavy chain antibody test diagnose a disease?
Not on its own. Elevated NfH indicates axonal injury but does not identify the cause, so results are interpreted with imaging, clinical history, and other lab tests. Most NfH assays are research or laboratory-developed tests rather than FDA-cleared stand-alone diagnostics, and a healthcare professional should interpret any result.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.